Pediatrix Medical Group (NYSE:MD) Upgraded by StockNews.com to “Buy” Rating

Pediatrix Medical Group (NYSE:MD) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

Several other analysts also recently commented on MD. Mizuho raised their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Jefferies Financial Group raised their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Truist Financial dropped their price target on Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating on the stock in a research note on Monday. Finally, Macquarie assumed coverage on Pediatrix Medical Group in a research report on Monday, December 16th. They set an “outperform” rating and a $18.00 price objective for the company. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $16.25.

Pediatrix Medical Group Trading Up 1.0 %

NYSE MD traded up $0.12 during trading on Thursday, reaching $12.73. 342,371 shares of the stock traded hands, compared to its average volume of 432,674. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $16.41. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -4.16, a price-to-earnings-growth ratio of 2.00 and a beta of 1.58. The stock’s 50-day moving average price is $14.35 and its 200 day moving average price is $11.54.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.29 EPS. Analysts predict that Pediatrix Medical Group will post 1.26 EPS for the current year.

Insider Activity

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pediatrix Medical Group

Hedge funds have recently added to or reduced their stakes in the business. Rubric Capital Management LP boosted its holdings in shares of Pediatrix Medical Group by 1.5% during the third quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company’s stock worth $95,907,000 after acquiring an additional 125,000 shares during the period. State Street Corp lifted its holdings in Pediatrix Medical Group by 1.4% during the 3rd quarter. State Street Corp now owns 3,540,791 shares of the company’s stock worth $41,038,000 after purchasing an additional 50,597 shares during the last quarter. Geode Capital Management LLC boosted its stake in Pediatrix Medical Group by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock valued at $22,452,000 after purchasing an additional 45,155 shares during the period. Dana Investment Advisors Inc. grew its holdings in Pediatrix Medical Group by 80.3% in the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after buying an additional 455,785 shares in the last quarter. Finally, Weiss Asset Management LP increased its position in Pediatrix Medical Group by 50.5% during the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after buying an additional 306,143 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.